Clinical trials: Ampulla of Vater Carcinoma
Pancreatic Cancer, Pancreas Cancer
Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy
The purpose of this study is to prospectively determine the effects of administering proton pump inhibitors (PPIs) following pancreaticoduodenectomy on postoperative outcomes.
- Conditions
- Pancreatic Cancer, Pancreas Cancer, Ampullary Cancer, Pancreas Neuroendocrine Tumor
- Trial name
- NCT05251233
- Testing
- Pantoprazole
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Washington University School of Medicine
Cancer Pain, Visceral Pain
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social function, as well as health related quality of life (HRQOL).
- Conditions
- Cancer Pain, Visceral Pain, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract
- Trial name
- NCT04907643
- Testing
- PICO G2 4k
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- Cedars-Sinai Medical Center
Biliary Tract Cancer, Cholangiocarcinoma
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC
Study consisted of an open-label, safety run-in part and a randomized, double-blind, placebo-controlled Phase 2/3 part. In the Phase 2/3 part, the study was evaluated whether bintrafusp alfa in combination with the current…
- Conditions
- Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer
- Trial name
- NCT04066491
- Testing
- M7824, Gemcitabine, Cisplatin
- Where
- 99 sites in United States, Argentina and 13 more
- Volunteers
- 309 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Hepatocellular Carcinoma, Cholangiocellular Carcinoma
Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers
This is a single arm phase II trial of Gemcitabine and Oxaliplatin (Gem-Ox) with Erlotinib (Tarceva) for the treatment of hepatocellular carcinoma (HCC) and biliary tree cancer (BTC) patients with platelet counts 100,000/µL.
- Conditions
- Hepatocellular Carcinoma, Cholangiocellular Carcinoma, Cholangiocarcinoma of the Extrahepatic Bile Duct, Bile Duct Cancer
- Trial name
- Gem-ox (NCT00832637)
- Testing
- Cisplatin, Erlotinib, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- New Mexico Cancer Research Alliance
Periampullary Cancers With Obstructive Jaundice, Pancreas Head Cancer
Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers
Preoperative biliary drainage methods include percutaneous transhepatic biliary drainage (PTBD), endoscopic nasobiliary drainage (ENBD), and endoscopic retrograde biliary drainage (ERBD).
- Conditions
- Periampullary Cancers With Obstructive Jaundice, Pancreas Head Cancer, Bile Duct Cancer, Ampulla of Vater Cancer
- Trial name
- NCT01134276
- Testing
- biliary drainage
- Where
- South Korea
- Volunteers
- 211 people
- Sponsor
- Seoul National University Hospital
Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma
Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma
This phase II trial tests how well giving gemcitabine, cisplatin and durvalumab alternating with pemigatinib for the treatment of biliary tract cancer with FGFR2 alterations that cannot be removed by surgery (unresectable), that…
- Conditions
- Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma, Locally Advanced Gallbladder Carcinoma
- Trial name
- NCT07780838
- Testing
- Biospecimen Collection, Cisplatin, Computed Tomography
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Cancer-associated Thrombosis, Esophageal Cancer
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
This is an open label, multi-center, and randomized phase II trial designed to compare the safety and efficacy of direct oral anticoagulants and subcutaneous dalteparin in patients with acute venous thromboembolism and upper…
- Conditions
- Cancer-associated Thrombosis, Esophageal Cancer, Stomach Cancer, Hepatocellular Carcinoma
- Trial name
- PRIORITY (NCT03139487)
- Testing
- Rivaroxaban, Dalteparin, apixaban
- Where
- South Korea
- Volunteers
- 176 people
- Sponsor
- Asan Medical Center
Colorectal Cancer, Gastric Cancer
Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy
The study is testing an intervention of an investigator-developed chemotherapy dose adjustment algorithm. The primary objective of this study is to evaluate the effectiveness of the chemotherapy dose adjustment algorithm for…
- Conditions
- Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Ampullary Cancer
- Trial name
- NCT04526886
- Testing
- Algorithm for cytopenia-related delay and dose-reduction of mFOLFOX chemotherapy
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Advanced Solid Tumors, HER2 Mutation
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety…
- Trial name
- panSOHO (NCT06760819)
- Testing
- BAY2927088
- Where
- 54 sites in United States, Australia and 9 more
- Volunteers
- 111 people
- Sponsor
- Bayer
Biliary Tract Cancer, Gallbladder Cancer
Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer
The primary objective of the trial is to determine the efficacy of VANDETANIB monotherapy or VANDETANIB plus GEMCITABINE or PLACEBO plus GEMCITABINE in prolonging the progression-free survival (PFS) at the trial closure in…
- Conditions
- Biliary Tract Cancer, Gallbladder Cancer, Cancer Of The Extrahepatic Bile Duct, Ampullary Carcinoma
- Trial name
- VANGOGH (NCT00753675)
- Testing
- ZD6474, Vandetanib, Gemcitabine
- Where
- 15 sites in Italy
- Volunteers
- 174 people
- Sponsor
- Genzyme, a Sanofi Company
Biliary Tract Cancer, Gallbladder Cancer
ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers
The purpose of this study is to determine the recommended phase II dose, and to assess the safety of acelarin in combination with cisplatin in patients with locally advanced/ metastatic biliary tract cancers.
- Conditions
- Biliary Tract Cancer, Gallbladder Cancer, Cholangiocarcinoma, Ampullary Cancer
- Trial name
- ABC-08 (NCT02351765)
- Testing
- Acelarin, Cisplatin
- Where
- 5 sites in United Kingdom
- Volunteers
- 21 people
- Sponsor
- The Christie NHS Foundation Trust
Pancreatic Cancer
Study of Stereotactic Body Radiation Therapy in Patients With Intact Pancreatic Cancer
This purpose of this study is to determine the highest tolerated dose of Stereotactic Body Radiation Therapy (SBRT) and also to determine the appropriate dose for intact pancreatic cancer.
- Trial name
- NCT01342354
- Testing
- Stereotactic Radiation 10 Gy, Stereotactic Radiation 12.5 Gy, Stereotactic Radiation 15 Gy
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Chicago
Solid Tumor
A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes.
- Trial name
- LODESTAR (NCT04171700)
- Testing
- Rucaparib
- Where
- 19 sites in United States
- Volunteers
- 83 people
- Sponsor
- pharmaand GmbH
Pancreatic Cancer, Cholangiocarcinoma
MicroRNAs as Bile-based Biomarkers in Pancreaticobiliary Cancers
pancreatic or biliary-tract cancer can be a serious diagnosis, as many patients present too late for surgery. Cancer cells have been found to release small messenger molecules called that regulate cancer genes called microRNAs…
- Conditions
- Pancreatic Cancer, Cholangiocarcinoma, Ampullary Cancer, Biliary Stricture
- Trial name
- MIRABILE (NCT06258824)
- Testing
- Small RNA Sequencing and Validation of candidate miRNAs
- Where
- United Kingdom
- Volunteers
- 229 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma of the Extrahepatic Bile Duct
Radioactive Stents for Treatment of Unresectable Biliary Tract Cancer
The purpose of this study is to determine whether radioactive stents and common used plastic stents are effective and safety in the treatment of unresectable biliary tract cancer.
- Conditions
- Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma of the Extrahepatic Bile Duct, Ampullary Carcinoma, Biliary Obstruction
- Trial name
- NCT02238613
- Testing
- radioactive stent, plastic stent
- Where
- China
- Volunteers
- 140 people
- Sponsor
- 307 Hospital of PLA
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the…
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
- Trial name
- NCT05462717
- Testing
- RMC-6291
- Where
- 64 sites in United States, Australia and 11 more
- Volunteers
- 222 people
- Sponsor
- Revolution Medicines, Inc.
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06128551
- Testing
- Elironrasib, Daraxonrasib
- Where
- 56 sites in United States, France and 5 more
- Volunteers
- 534 people
- Sponsor
- Revolution Medicines, Inc.
Adenocarcinoma of Head of Pancreas, Cholangio Carcinoma
Pancreatic Head and Peri-ampullary Cancer Laparoscopic vs Open Surgical Treatment Trial (PLOT)
The aim of this study is to compare the two surgical approaches namely laparoscopic pancreatoduodenectomy and open pancreatoduodenectomy for management of periampullary and pancreatic head cancers in terms of parameters like…
- Conditions
- Adenocarcinoma of Head of Pancreas, Cholangio Carcinoma, Duodenal Adenocarcinoma, Carcinoma of Ampulla of Vater
- Trial name
- PLOT (NCT02081131)
- Testing
- Open surgery, Laparoscopic surgery
- Where
- India
- Volunteers
- 64 people
- Sponsor
- GEM Hospital & Research Center
Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc)
Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer
The purpose of this study is to evaluate the anti-tumor efficacy of daraxonrasib monotherapy in patients with unresectable or advanced/metastatic, KRAS-mutant BTC who have progressed on or are intolerant of 1st line systemic…
- Conditions
- Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma
- Trial name
- NCT07793253
- Testing
- Daraxonrasib
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic
INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
Phase 2 study to evaluate the clinical activity of INCMGA00012 in patients with Unresectable or metastatic Adenosquamous Pancreatic or Ampullary Cancer.
- Trial name
- NCT04116073
- Testing
- INCMGA00012 (PD-1 antibody)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins